C‐Reactive Protein Changes in Adult and Pediatric People With Cystic Fibrosis During Treatment of Pulmonary Exacerbations
Jonathan B. Zuckerman(Maine Medical Center), Alex H. Gifford(Rainbow Babies & Children's Hospital), Deepika Polineni(Washington University in St. Louis), Alexandra C. Hinton(Maine Medical Center), Samya Z. Nasr(University of Michigan), Joel Mermis(University of Kansas), Shijing Jia(University of Michigan), Rebecca Dezube(Johns Hopkins University), Hossein Sadeghi(Columbia University Irving Medical Center), Thomas Lahiri(University of Vermont Medical Center), Emily DiMango(Columbia University Irving Medical Center), Elliott C. Dasenbrook(Cleveland Clinic), Edith T. Zemanick(Children's Hospital Colorado), Charlotte C. Tenebäck(University of Vermont Medical Center), Natalie E. West(Johns Hopkins University)
Cited by 1
Related Papers
Persistent Methicillin-resistant <i>Staphylococcus aureus</i> and Rate of FEV1 Decline in Cystic Fibrosis
|American Journal of Respiratory and Critical Care Medicine|2008|322
Antibiotic Management of Lung Infections in Cystic Fibrosis. I. The Microbiome, Methicillin-Resistant <i>Staphylococcus aureus</i> , Gram-Negative Bacteria, and Multiple Infections
|Annals of the American Thoracic Society|2014|198
Prevalence and risk factors for recovery of filamentous fungi in individuals with cystic fibrosis
|Journal of Cystic Fibrosis|2010|130